Moleculin Biotech Inc (MBRX)
2.88
+0.05
(+1.77%)
USD |
NASDAQ |
Nov 22, 14:28
Moleculin Biotech Net Income (Quarterly): -10.59M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -10.59M |
June 30, 2024 | -4.319M |
March 31, 2024 | -4.97M |
December 31, 2023 | -10.27M |
September 30, 2023 | -5.609M |
June 30, 2023 | -5.976M |
March 31, 2023 | -7.915M |
December 31, 2022 | -6.77M |
September 30, 2022 | -8.611M |
June 30, 2022 | -6.777M |
March 31, 2022 | -6.867M |
December 31, 2021 | -2.825M |
September 30, 2021 | -4.379M |
June 30, 2021 | -4.244M |
March 31, 2021 | -4.445M |
December 31, 2020 | -2.639M |
September 30, 2020 | -3.395M |
June 30, 2020 | -10.11M |
Date | Value |
---|---|
March 31, 2020 | -1.209M |
December 31, 2019 | -3.797M |
September 30, 2019 | -4.145M |
June 30, 2019 | -1.221M |
March 31, 2019 | -4.041M |
December 31, 2018 | -2.785M |
September 30, 2018 | -2.038M |
June 30, 2018 | -5.125M |
March 31, 2018 | -1.927M |
December 31, 2017 | -3.185M |
September 30, 2017 | -2.866M |
June 30, 2017 | -3.424M |
March 31, 2017 | -0.329M |
December 31, 2016 | -1.423M |
September 30, 2016 | -1.432M |
June 30, 2016 | -0.739M |
March 31, 2016 | -0.332M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-10.59M
Minimum
Sep 2024
-1.209M
Maximum
Mar 2020
-5.786M
Average
-5.290M
Median
Net Income (Quarterly) Benchmarks
Agilent Technologies Inc | 282.00M |
Seelos Therapeutics Inc | 1.71M |
Cara Therapeutics Inc | -12.48M |
Citius Pharmaceuticals Inc | -10.57M |
NovaBay Pharmaceuticals Inc | -1.212M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 7.135M |
EPS Diluted (Quarterly) | -2.85 |
Enterprise Value | -0.9096M |
Earnings Yield | -408.9% |